



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 126036

TO: Olga Chernyshev
Location: REM-4E84/4C70
Art Unit: 1646
Friday, June 04, 2004

Case Serial Number: 10/099880

From: Peggy Ruppel
Location: Biotech-Chem Library
REMSEN 1B65
Phone: 571-272-2557

Peggy.Ruppel@uspto.gov

Search Notes

The results for your search request are attached. Most of the records related to the use of anti-beta-amyloid antibodies for the treatment of Alzheimer's, so I selected only those records that were either ambiguous in their content or specified the relationship of the antibody levels to diagnosis.

Please let me know if you have any comments or questions.

Thank you for using STIC services.

=> b zcaplus
FILE 'ZCPLUS' ENTERED AT 13:28:44 ON 04 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 4 Jun 2004 VOL 140 ISS 24
FILE LAST UPDATED: 3 Jun 2004 (20040603/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 122
L2 (165834) SEA FILE=ZCPLUS ABB=ON PLU=ON ANTIBODIES/CT
L4 (16634) SEA FILE=ZCPLUS ABB=ON PLU=ON ALZHEIMER?/CT,CW
L10 1035 SEA FILE=ZCPLUS ABB=ON PLU=ON 107761-42-2/RN
L13 1002 SEA FILE=ZCPLUS ABB=ON PLU=ON L10(L) (ANST OR ANT OR ARG OR ARU OR USES OR BUU OR DGN OR BIOL)/RL
L14 57 SEA FILE=ZCPLUS ABB=ON PLU=ON L13 AND L2
L15 43 SEA FILE=ZCPLUS ABB=ON PLU=ON L4 AND L14
L16 18 SEA FILE=ZCPLUS ABB=ON PLU=ON L15 AND P/DT
L17 18 SEA FILE=ZCPLUS ABB=ON PLU=ON (ANTI(W)BETA(W)AMYLOID?) (2A) AN TIBOD?
L20 8 SEA FILE=ZCPLUS ABB=ON PLU=ON L17 AND P/DT
L21 26 SEA FILE=ZCPLUS ABB=ON PLU=ON L20 OR L16
L22 22 SEA FILE=ZCPLUS ABB=ON PLU=ON L21 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)

=> b medline
FILE 'MEDLINE' ENTERED AT 13:28:56 ON 04 JUN 2004

FILE LAST UPDATED: 3 JUN 2004 (20040603/UP). FILE COVERS 1951 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details. OLDMEDLINE now back to 1951.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que l29

L23	5725	SEA FILE=MEDLINE ABB=ON	PLU=ON	AMYLOID BETA-PROTEIN/CT
L24	61360	SEA FILE=MEDLINE ABB=ON	PLU=ON	ANTIBODIES/CT,CW
L25	2583	SEA FILE=MEDLINE ABB=ON	PLU=ON	L24 (L) BL
L26	10	SEA FILE=MEDLINE ABB=ON	PLU=ON	L23 AND L25
L27	32098	SEA FILE=MEDLINE ABB=ON	PLU=ON	ALZHEIMER DISEASE/CT
L28	5395	SEA FILE=MEDLINE ABB=ON	PLU=ON	L27 (L) DI
L29	0	SEA FILE=MEDLINE ABB=ON	PLU=ON	L26 AND L28

=> b embase

FILE 'EMBASE' ENTERED AT 13:29:08 ON 04 JUN 2004
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE COVERS 1974 TO 4 Jun 2004 (20040604/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que l51

L31	7077	SEA FILE=EMBASE ABB=ON	PLU=ON	AMYLOID BETA PROTEIN/CT,CW
L32	168331	SEA FILE=EMBASE ABB=ON	PLU=ON	D4.680.350./CT
L35	25	SEA FILE=EMBASE ABB=ON	PLU=ON	(AMYLOID (A) PROTEIN) (2A) ANTIBOD?
L36	168331	SEA FILE=EMBASE ABB=ON	PLU=ON	L31 OR L32
L37	37899	SEA FILE=EMBASE ABB=ON	PLU=ON	ANTIBODY/CT,CW
L38	2920	SEA FILE=EMBASE ABB=ON	PLU=ON	L37 AND L36
L39	2944	SEA FILE=EMBASE ABB=ON	PLU=ON	L35 OR L38
L40	39635	SEA FILE=EMBASE ABB=ON	PLU=ON	ALZHEIMER DISEASE/CT
L41	6482	SEA FILE=EMBASE ABB=ON	PLU=ON	L40 (L) DI
L42	16	SEA FILE=EMBASE ABB=ON	PLU=ON	L39 AND L41
L51	11	SEA FILE=EMBASE ABB=ON	PLU=ON	L42 AND PY<=2001

=> b biosis

FILE 'BIOSIS' ENTERED AT 13:29:15 ON 04 JUN 2004
 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
 FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 2 June 2004 (20040602/ED)

FILE RELOADED: 19 October 2003.

=> d que l50

L43	109	SEA FILE=BIOSIS ABB=ON	PLU=ON	("BETA AMYLOID"/CT OR "BETA AMYLOID -40"/CT OR "BETA AMYLOID -42"/CT OR "BETA AMYLOID 1-40"/CT OR "BETA AMYLOID 1-42"/CT) OR "BETA AMYLOID 42"/CT OR ("BETA AMYLOID PEPTIDE"/CT OR "BETA AMYLOID PEPTIDE 1-40"/CT OR "BETA AMYLOID PEPTIDE 1-42"/CT) OR "BETA AMYLOID PEPTIDES"/CT OR ("BETA AMYLOID PRECURSOR"/CT OR "BETA AMYLOID PRECURSOR PROTEIN"/CT) OR ("BETA AMYLOID-1-40"/CT OR "BETA AMYLOID-1-42"/CT)
L44	1	SEA FILE=BIOSIS ABB=ON	PLU=ON	"BETA AMYLOID ANTIBODIES"/CT
L45	31694	SEA FILE=BIOSIS ABB=ON	PLU=ON	ANTIBODIES/CT,CW
L46	5	SEA FILE=BIOSIS ABB=ON	PLU=ON	L43 AND L45

L47 5 SEA FILE=BIOSIS ABB=ON PLU=ON L44 OR L46
 L48 19378 SEA FILE=BIOSIS ABB=ON PLU=ON ALZHEIMER DISEASE/CT,CW
 L49 3 SEA FILE=BIOSIS ABB=ON PLU=ON L47 AND L48
 L50 1 SEA FILE=BIOSIS ABB=ON PLU=ON L49 AND PY<=2001

=> dup rem 150 129 151 122
 L29 HAS NO ANSWERS
 FILE 'BIOSIS' ENTERED AT 13:29:58 ON 04 JUN 2004
 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 13:29:58 ON 04 JUN 2004
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ZCPLUS' ENTERED AT 13:29:58 ON 04 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
 PROCESSING COMPLETED FOR L50
 PROCESSING COMPLETED FOR L29
 PROCESSING COMPLETED FOR L51
 PROCESSING COMPLETED FOR L22
 L52 34 DUP REM L50 L29 L51 L22 (0 DUPLICATES REMOVED)

=> => d all 152 6 7 8 9 11 12 17 24 27 30 33 34
 YOU HAVE REQUESTED DATA FROM FILE 'ZCPLUS, BIOSIS, EMBASE' - CONTINUE? (Y)/N:y

L52 ANSWER 6 OF 34 ZCPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:281947 ZCPLUS
 DN 138:270300
 ED Entered STN: 11 Apr 2003
 TI Anti-amyloid beta-derived diffusible ligand (ADDL) antibodies and uses thereof
 IN Klein, William L.; Krafft, Grant A.; Lambert, Mary P.; Viola, Kirsten L.; Chromy, Brett A.; Gong, Yue Song; Chang, Lei; Morgan, Todd E.; Rozofsky, Irina; Finch, Caleb E.
 PA USA
 SO U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 369,236.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K039-395
 NCL 424130100
 CC 15-3 (Immunochemistry)
 Section cross-reference(s): 1, 14
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003068316	A1	20030410	US 2002-166856	20020611 <--
	US 6218506	B1	20010417	US 1997-796089	19970205 <--
	WO 2003104437	A2	20031218	WO 2003-US19640	20030611
	WO 2003104437	A3	20040226		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2004091492	A2	20040325	JP 2003-343836	20031001 <--
PRAI US 1997-796089	A2	19970205 <--		
US 1998-95264P	P	19980804 <--		
US 1999-369236	A2	19990804 <--		
JP 1998-533262	A3	19980205 <--		
US 2002-166856	A	20020611		

AB The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compds. that block the formation or activity of ADDLs, and methods of identifying such compds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

ST Alzheimers disease diagnosis therapy amyloid beta antibody; neurodegenerative disease diagnosis therapy amyloid beta antibody

IT Immunoglobulins
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (G; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Neuroglia
 (activation; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT **Alzheimer's disease**
 Cerebrospinal fluid
 Diagnosis
 Drug screening
 Human
 Signal transduction, biological
 (anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT **Antibodies**
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Nervous system, disease
 (degeneration; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Memory, biological
 (disorder; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (for ADDL; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Neurotransmission
 (long-term potentiation; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Nerve
 (neuron; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Toxicity
 (neurotoxicity; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Nerve
 (toxicity; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Peptides, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tryptic; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT Amyloid
 RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
 (β -; anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT 107761-42-2, Amyloid β 1-42
 RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use);
 ; BIOL (Biological study); USES (Uses)
 (anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT 141349-87-3, Fyn tyrosine kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

IT 303-45-7, Gossypol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-ADDL antibodies and their use in therapy, diagnosis, and drug screening for Alzheimer's disease and other neurodegenerative diseases)

L52 ANSWER 7 OF 34 ZCPLUS COPYRIGHT 2004 ACS on STN

AN 2003:4867 ZCPLUS

DN 138:35750

ED Entered STN: 03 Jan 2003

TI Monoclonal antibody mbAb 1E8 that is specific for the first two amino-terminal amino acids of beta-amyloid peptides and its use in the detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids

IN Wiltfang, Jens; Dyrks, Thomas; Moenning, Ursula

PA Germany

SO Eur. Pat. Appl., 82 pp.

CODEN: EPXXDW

DT Patent

LA German

IC ICM C07K016-18

ICS G01N033-561; G01N033-539; G01N033-577; G01N033-541; G01N033-68;
 G01N033-50

CC 9-10 (Biochemical Methods)

Section cross-reference(s) : 14, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1270592	A1	20030102	EP 2001-114192	20010612 <-- R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR US 2003166019 A1 20030904 US 2002-170272 20020611 <--
PRAI	EP 2001-114192	A	20010612 <--		
AB	The invention concerns the monoclonal antibody that is specific for the first two amino-terminal amino acids of beta-amyloid peptides and its use in the detection of beta-amyloid peptides and β -amyloid precursor protein (sAPPa) in a western immunoblot procedure. The monoclonal antibody can be radiolabeled. Body fluid samples are treated in a denaturating medium followed by electrophoresis; mbAb 1E8 is used for identifying A β 1-37, A β 1-38, A β 1-39, A β 1-40, A β 1-42.				
ST	monoclonal antibody beta amyloid peptide western blot Alzheimers disease				
IT	Immunoassay (immunoblotting; monoclonal antibody mbAb 1E8 that is specific for first two amino-terminal amino acids of beta-amyloid peptides and its use in detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids)				
IT	Alzheimer's disease Blood analysis Blood plasma Body fluid Brain Cerebrospinal fluid Human (monoclonal antibody mbAb 1E8 that is specific for first two amino-terminal amino acids of beta-amyloid peptides and its use in detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids)				
IT	Amyloid precursor proteins RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (monoclonal antibody mbAb 1E8 that is specific for first two amino-terminal amino acids of beta-amyloid peptides and its use in detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids)				
IT	Antibodies RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (monoclonal, mbAb 1E8; monoclonal antibody mbAb 1E8 that is specific for first two amino-terminal amino acids of beta-amyloid peptides and its use in detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids)				
IT	Amyloid RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (β -; monoclonal antibody mbAb 1E8 that is specific for first two amino-terminal amino acids of beta-amyloid peptides and its use in detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids)				
IT	107761-42-2, Amyloid β 1-42 115427-62-8 131438-74-9 131438-79-4, β -Amyloid peptide 1-40 186359-67-1 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES				

(Uses)

(monoclonal antibody mbAb 1E8 that is specific for first two amino-terminal amino acids of beta-amyloid peptides and its use in detection of beta-amyloid peptides and sAPPa in brain tissues and body fluids)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Arai, T; BRAIN RESEARCH 1999, 1/2
- (2) Chevallier, N; BRAIN RESEARCH 1997, 1/2
- (3) Klafki, H; ANALYTICAL BIOCHEMISTRY 1996
- (4) Saido, T; THE JOURNAL OF BIOLOGICAL CHEMISTRY 1994, 21, ZCPLUS
- (5) Wiltfang, J; ELECTROPHORESIS 1997

L52 ANSWER 8 OF 34 ZCPLUS COPYRIGHT 2004 ACS on STN

AN 2002:736057 ZCPLUS

DN 137:246514

ED Entered STN: 27 Sep 2002

TI Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder

IN Weksler, Marc E.; Szabo, Paul

PA Cornell Research Foundation, Inc., USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 15-1 (Immunochemistry)

Section cross-reference(s): 1, 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074240	A2	20020926	WO 2002-US7883	20020315 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-276659P P 20010316 <--

AB The invention provides a method for assessing risk of a neurodegenerative disease or disorder in a subject. The method comprises comparing a level of anti-amyloid peptide antibody in a biol. sample from a subject to a normal level, wherein a lower level in the biol. sample from the subject indicates the presence of the disease or disorder. In a specific embodiment, the disease or disorder is Alzheimer's Disease (AD); in a further specific embodiment, the amyloid peptide is β -amyloid-42 (A β 42). In addition, the discovery that certain neurodegenerative diseases or disorders are associated with a deficiency of anti-amyloid antibodies provides a method of treating such a disease or disorder in a subject. This method comprises administering a therapeutically effective amount of a human anti-amyloid peptide antibody to a subject believed to suffer from the immune deficiency or disorder. For example, the disease or disorder can be Alzheimer's Disease (AD). In such an embodiment, the amyloid peptide can be β -amyloid-42 (A β 42).

ST amyloid antibody diagnosis neurol disease disorder

IT Apolipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (E4; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Immunoglobulins
 - RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (G; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Aging, animal
 - Alzheimer's disease**
 - Biological materials
 - Blood
 - Blood analysis
 - Blood plasma
 - Blood serum
 - Brain
 - Diagnosis
 - Drugs
 - Human
 - Immunoassay
 - Immunodeficiency
 - Nervous system, disease
 - (anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Immunoglobulins
 - RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT **Antibodies**
 - RL: ANT (Analyte); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Amyloid
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Mental disorder
 - (cognitive; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Nervous system, disease
 - (degeneration; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Cognition
 - Memory, biological
 - (disorder; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT Immunoassay
 - (enzyme-linked immunosorbent assay; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT **Alzheimer's disease**
 - (familial; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT **Antibodies**
 - RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 - (monoclonal; anti-amyloid antibody based diagnosis and treatment of a neurol. disease or disorder)
- IT **107761-42-2, Glycopeptide (human clone 9-110 amyloid A4 peptide moiety)**
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(anti-amyloid antibody based diagnosis and treatment of a neurologic disease or disorder)

L52 ANSWER 9 OF 34 ZCPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:465724 ZCPLUS
 DN 137:46063
 ED Entered STN: 21 Jun 2002
 TI β -Secretase transgenic mouse and anti- β -secretase antibodies: diagnosis and therapy of Alzheimer's disease
 IN Wong, Philip C.; Cai, Huabin; Price, Donald L.
 PA The Johns Hopkins University School of Medicine, USA
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC C07K
 CC 15-3 (Immunochemistry)
 Section cross-reference(s): 1, 7, 14
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002047466	A2	20020620	WO 2001-US50771	20011029 <--
	WO 2002047466	A3	20030123		
	W: AM, AT, BA, BR, BY, BZ, CH, CN, CU, CZ, DK, DM, ES, FI, GB, HR, HU, ID, IL, IN, KG, KR, LK, LR, LT, LU, MD, MG, MW, PH, PL, RO, RU, SD, SE, SI, SK, TJ, TM, TR, TT, TZ, VN, ZA, AM, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, BE, CY, DK, ES, FI, GB, GR, IE, NL, PT, CG, CI, GA, GN, MR, NE, SN, TD, TG				
	AU 2002043391	A5	20020624	AU 2002-43391	20011029 <--
PRAI	US 2000-244051P	P	20001027 <--		
	US 2000-708096	A	20001103 <--		
	WO 2001-US50771	W	20011029 <--		
AB	The authors disclose the preparation and characterization of transgenic mice which harbor a transgene that eliminates the expression of the β -secretase, BACE1. In addition, antibodies specific for BACE1 are provided. The transgenic mice may be suitable for diagnosing a neurodegenerative disease, including Alzheimer's disease, and for identifying agents that modulate or treat Alzheimer's disease.				
ST	beta secretase antibody Alzheimer disease; amyloid precursor processing beta secretase neuron				
IT	Transgene RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (antisense; for β -secretase)				
IT	Amyloidosis (detection and inhibition of β -secretase activity in transgenic animal with)				
IT	Human (detection of β -secretase activity in diagnosis and treatment of Alzheimer's disease)				
IT	Blood analysis Cerebrospinal fluid PCR (polymerase chain reaction) (detection of β -secretase activity in diagnosis of Alzheimer's disease)				
IT	Memory, biological (disorder; detection and inhibition of β -secretase activity in transgenic animal with expression of)				
IT	Amyloid precursor proteins RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST				

(Analytical study); BIOL (Biological study)
 (expression in transgenic animal and inhibition of β -secretase-mediated processing of)

IT Test kits
 (for detection of β -secretase and amyloid peptides)

IT Retroviral vectors
 (for gene targeting of β -secretase in embryonic stem cells)

IT Drug screening
 (for inhibitors of β -secretase)

IT Immunoassay
 (for β -secretase in diagnosis of Alzheimer's disease)

IT mRNA
 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (for β -secretase in diagnosis of Alzheimer's disease)

IT Immunoglobulins
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (fragments; to amyloid peptides)

IT Gene targeting
 (gene knock-out; of BACE1 in mouse)

IT Antisense DNA
 Antisense RNA
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of β -secretase by)

IT Anti-Alzheimer's agents
 (inhibitors of β -secretase)

IT Antibodies
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (labeled; to amyloid peptides)

IT Antibodies
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
 DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (monoclonal; to β -secretase)

IT Nerve
 (neuron, cortical; β -secretase expression and amyloid precursor processing in)

IT Diagnosis
 (of Alzheimer's disease by detection of β -secretase activity)

IT Bioassay
 (of β -secretase activity in transgenic animal)

IT Embryo, animal
 (stem cell; prepare of transgenic animal by gene targeting of β -secretase in)

IT Aves
 Capra
 Cattle
 Mouse
 Sheep
 Swine
 (targeted knockout of BACE1 β -secretase gene in)

IT Antibodies
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
 DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (to β -secretase)

IT 158736-49-3, β -Secretase
 RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use); BIOL

(Biological study); USES (Uses)
 (inhibition of amyloid peptide production by)

IT 107761-42-2, Glycopeptide (human clone 9-110 amyloid A4 peptide moiety) 131438-79-4 157802-70-5 338458-53-0
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte);
 DGN (Diagnostic use); ANST (Analytical study); BIOL
 (Biological study); USES (Uses)
 (inhibition of β -secretase-mediated production of)

IT 437973-94-9 437973-95-0 437973-96-1
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; β -Secretase transgenic mouse and anti- β -secretase antibodies, diagnosis and therapy of Alzheimer's disease)

L52 ANSWER 11 OF 34 ZCPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:449710 ZCPLUS
 DN 137:17435
 ED Entered STN: 14 Jun 2002
 TI Compositions and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease
 IN Chojkier, Mario; Buck, Martina
 PA USA
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07K014-47
 ICS G01N033-53; C07K016-18
 CC 9-10 (Biochemical Methods)
 Section cross-reference(s): 1, 14, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046222	A2	20020613	WO 2001-US43676	20011121 <--
	WO 2002046222	A3	20030508		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002137112	A1	20020926	US 2000-731460	20001207 <--
	US 6495335	B2	20021217		
	AU 2002019824	A5	20020618	AU 2002-19824	20011121 <--
	EP 1339743	A2	20030903	EP 2001-999575	20011121 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2003104488	A1	20030605	US 2002-278181	20021021 <--
PRAI	US 2000-731460	A	20001207 <--		
	WO 2001-US43676	W	20011121 <--		
AB	The present invention provides methods and compns. for the diagnosis of Alzheimer's disease. In particular, the present invention provides modified beta-amyloid peptides, antibodies that specifically bind to the modified beta-amyloid peptides, and methods for using these compns. in the diagnosis of Alzheimer's disease, as well as methods to monitor treatment and/or disease progression of Alzheimer's disease in patients. The present invention also provides compns. and methods useful in research				

involving amyloid precursor protein (APP) metabolism and Alzheimer's disease.

ST diagnosing Alzheimer disease modified beta amyloid peptide; antibody

modified beta amyloid peptide Alzheimer disease

IT Brain
 (anal. of tissue of; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Antisera

Ascitic fluid

Cerebrospinal fluid
 (anal. of; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT **Antibodies**
 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (autoantibodies; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Brain
 (cerebral cortex, anal. of tissue of; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Immunoassay
 (competitive, ELISA; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT **Alzheimer's disease**

Blood analysis

Diagnosis

Human

Test kits
 (compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT **Antibodies**
 RL: ANT (Analyte); ARG (Analytical reagent use); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Amyloid precursor proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Hybridoma
 (conditioned culture medium, anal. of; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Enzymes, biological studies
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (conjugates, with antibody; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT **Antibodies**
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (conjugates; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT Hemocyanins
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (conjugation with modified peptide; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing

- IT Alzheimer's disease)
- IT Immunoassay
 - (enzyme-linked immunosorbent assay; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **Alzheimer's disease**
 - (familial; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **Antibodies**
 - RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (immobilized; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT Immunoassay
 - (immunoblotting; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **Anti-Alzheimer's agents**
 - (monitoring treatment with; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT Peptides, analysis
 - RL: ANT (Analyte); ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (of modified β-amyloid; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT Body fluid
 - (serous fluid, anal. of; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **Alzheimer's disease**
 - (sporadic; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **Alzheimer's disease**
 - (type I; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **Alzheimer's disease**
 - (type II; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT Amyloid
 - RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (β-, modified peptides; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT **107761-42-2, Glycopeptide (human clone 9-110 amyloid A4 peptide moiety)**
 - RL: BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 - (amino acid sequence; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT 542-78-9D, Malondialdehyde, adducts with β-amyloid peptide
 - RL: ANT (Analyte); ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)
- IT 9001-78-9D, conjugates with antibody 9002-13-5D, Urease, conjugates with antibody 9003-99-0D, Peroxidase, conjugates with antibody 9031-11-2D,

β -Galactosidase, conjugates with antibody 9032-08-0D, Glucoamylase, conjugates with antibody
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT 107761-42-2DP, Glycopeptide (human clone 9-110 amyloid A4 peptide moiety), adducts with malondialdehyde
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

IT 56-87-1D, L-Lysine, adducts with Malondialdehyde
 RL: ANT (Analyte); ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (in modified β -amyloid peptide; compns. and methods based on modified beta-amyloid peptides and antibodies for diagnosing Alzheimer's disease)

L52 ANSWER 12 OF 34 ZCPLUS COPYRIGHT 2004 ACS on STN

AN 2002:185445 ZCPLUS

DN 136:246397

ED Entered STN: 15 Mar 2002

TI Chimeric antibody comprising fragment of **anti- β - amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases

IN Nicolau, Yves Claude

PA Aventis Pharma S.A., Fr.; Universite Louis Pasteur

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-68

CC 15-3 (Immunochemistry)

Section cross-reference(s): 3, 9

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 2002021141	A2	20020314	WO 2001-US27632	20010906 <--
WO 2002021141	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001090638	A5	20020322	AU 2001-90638	20010906 <--
US 2002156036	A1	20021024	US 2001-948049	20010906 <--
EP 1317479	A2	20030611	EP 2001-970656	20010906 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI US 2000-230391P	P	20000906	<--	
US 2000-255033P	P	20001212	<--	
WO 2001-US27632	W	20010906	<--	

AB The present invention generally relates to the detection, treatment or

prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compns. comprising therapeutic vaccines, antisera and mol. constructs, comprising expression vectors and fusion proteins encoded therein. The fusion proteins comprise light chain variable domain of monoclonal antibody 6C6 recognizing β -amyloid epitope and capable of solubilizing β -amyloid fibers and tangles. The fusion proteins also comprise fragment of transferrin capable of crossing blood brain barrier.

ST Amyloid

IT Amyloid

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(A; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Immunoglobulins

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(AL (amyloid light-chain); chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Brain, disease

Prion diseases

(Creutzfeldt-Jakob; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Apolipoproteins

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(E4, allele; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Amyloidosis

(Gertsmann-Straussler-Scheinker syndrome; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Parkinson's disease

(Guamanian parkinsonism-dementia; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Amyloidosis

(Muckle-Wells syndrome; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Aging, animal

(accelerated; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Immunostimulants

(adjuvants; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and

transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Disease, animal
 (amyloid-associated; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6**
 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Heart, disease
 (amyloidosis, familial; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal
antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Brain, disease
 (amyloidosis, senile; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal
antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Heart, disease
 (amyloidosis; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and
 transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Amyloidosis
 (atrial; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and
 transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

IT Alzheimer's disease
 Amyloidosis
 Animal
 Antiserums
 Blood-brain barrier
 DNA sequences
 Deafness
 Down's syndrome
 Endocrine system, neoplasm
 Epitopes
 Genetic vectors
 Human
 Molecular cloning
 Multiple myeloma
 Multiple sclerosis
 Protein sequences
 Thyroid gland, neoplasm
 Urticaria
 Vaccines
 (chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin
 fragment for treating and diagnosing amyloidosis-associated diseases)

IT Gelsolin
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin
 fragment for treating and diagnosing amyloidosis-associated diseases)

IT Antibodies
 Fusion proteins (chimeric proteins)
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)

- (chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Transferrins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Artery, disease
 (coronary; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Nervous system, disease
 (degeneration; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Mental disorder
 (diffuse Lewy body disease; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Immunoassay
 (enzyme-linked immunosorbent assay; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
 (familial Mediterranean fever; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Fever and Hyperthermia
 (familial Mediterranean; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Kidney, disease
 (familial amyloid nephropathy; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
 (familial amyloidotic polyneuropathy, type IV; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
 (familial amyloidotic polyneuropathy; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody** 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (fragments; chimeric antibody comprising fragment of **anti-**

- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Dialysis
(hemodialysis, chronic; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
(hereditary, cerebral hemorrhage type, Dutch type; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
(hereditary; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Pancreatic islet of Langerhans, neoplasm
(insulinoma, amylin; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Drug delivery systems
(liposomes; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Macroglobulins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(macroglobulinemia; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Brain, disease
Prion diseases
(mad cow; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Thyroid gland, neoplasm
(medullary carcinoma; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Antibodies
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and

- transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Lipid A
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monophosphates; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6**
 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Diabetes mellitus
 Diabetes mellitus
 (non-insulin-dependent; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Paralysis
 (pseudobulbar; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Brain, disease
 Prion diseases
 (scrapie; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
 (secondary; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
 (senile, cardiac; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloidosis
 (senile; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Head, disease
 (trauma; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT Amyloid
 RL: ADV (Adverse effect, including toxicity); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (β -; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal **antibody 6C6** and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
- IT 403973-32-0P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; chimeric antibody comprising fragment of **anti- β -amyloid** monoclonal

IT antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 56645-65-9, Procalcitonin 91448-99-6, Cystatin C
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 56-87-1, L-Lysine, reactions 112-67-4, Palmitoyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 20257-67-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 57-88-5, Cholesterol, biological studies 18656-38-7,
 Dimyristoyl-phosphatidylcholine 61361-72-6,
 Dimyristoylphosphatidylglycerol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 403973-33-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (nucleotide sequence; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 403974-94-7, 3: PN: WO0221141 SEQID: 3 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)
 IT 403974-95-8
 RL: PRP (Properties)
 (unclaimed protein sequence; chimeric antibody comprising fragment of anti- β -amyloid monoclonal antibody 6C6 and transferrin fragment for treating and diagnosing amyloidosis-associated diseases)

L52 ANSWER 17 OF 34 ZCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:185883 ZCAPLUS
 DN 134:236224
 ED Entered STN: 16 Mar 2001
 TI Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
 IN Solomon, Beka; Frenkel, Dan; Hanan, Eilat
 PA Ramot University Authority for Applied Research & Industrial Development, Israel
 SO PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N

CC 15-2 (Immunochemistry)
 Section cross-reference(s) : 3, 63
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001018169	A2	20010315	WO 2000-IL518	20000831 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US	6703015	B1	20040309	US 1999-473653	19991229 <--
EP	1180938	A2	20020227	EP 2000-954883	20000831 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO				
JP	2003509020	T2	20030311	JP 2001-522381	20000831 <--
US	2004013647	A1	20040122	US 2003-384788	20030311 <--
US	2004052766	A1	20040318	US 2003-618856	20030715 <--
PRAI	US 1999-152417P	P	19990903	<--	
	US 1999-473653	A	19991229	<--	
	US 2000-629971	A	20000731	<--	
	WO 2000-IL518	W	20000831	<--	
	US 2001-808037	B2	20010315	<--	
	US 2001-830954	A2	20010807	<--	
	US 2002-371735P	P	20020412		
	US 2002-162889	A2	20020606		
AB	A method of immunizing against plaque forming diseases using display technol. is provided. The method utilizes novel agents, or pharmaceutical compns. for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compns. for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.				
ST	prion protein epitope vaccine plaque forming disease; beta amyloid antibody plaque forming disease				
IT	Amyloid				
	RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)				
	(A, serum; display vehicles encoding human PrP epitope or anti-β amyloid antibody scFv for diagnosing and/or treating or preventing plaque forming diseases)				
IT	Brain, disease				
	Prion diseases				
	(Creutzfeldt-Jakob; display vehicles encoding human PrP epitope or anti-β amyloid antibody scFv for diagnosing and/or treating or preventing plaque forming diseases)				
IT	Immunoglobulins				
	RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)				
	(G, κ light chain; display vehicles encoding human PrP epitope or anti-β amyloid antibody scFv for diagnosing and/or treating or preventing plaque forming diseases)				

- IT Prion diseases
 (Gerstmann-Sträussler-Scheinker disease; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Immunoglobulins
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (M; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Amyloidosis
 (SAA; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Proteins, specific or class
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); MFM (Metabolic formation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (aggregating; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Primate
 (and human; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Peptides, biological studies
 Proteins, general, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (carrier; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Drug delivery systems
 (carriers, polypeptide; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Proteins, specific or class
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (coat, bacteriophage; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Animal tissue
 Animal virus
 Bacteria (Eubacteria)
 Bacteriophage
 Body fluid
 Cat (*Felis catus*)
 Cattle
 Coliphage fd
 DNA sequences
 Deer
 Dog (*Canis familiaris*)
 Elk
 Escherichia coli
 Filamentous bacteriophage
 Molecular cloning
 Monkey

- Multiple myeloma
- Phage display
- Protein sequences
- Sheep
- Swine
 - (display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Prion proteins
 - RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 - (display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Antibodies
 - Fusion proteins (chimeric proteins)
 - RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Animal virus
 - (double stranded DNA; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv
 - for diagnosing and/or treating or preventing plaque forming diseases)
- IT Immunoassay
 - (enzyme-linked immunosorbent assay; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Prion diseases
 - (fatal familial insomnia; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Immunoglobulins
 - RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (fragments, scFv; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv
 - for diagnosing and/or treating or preventing plaque forming diseases)
- IT Glycoproteins, specific or class
 - RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (gpVIII; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Brain, disease
 - (hereditary Icelandic syndrome; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Prion diseases
 - (kuru; display vehicles encoding human PrP epitope or **anti- β amyloid antibody** scFv for diagnosing and/or treating or preventing plaque forming diseases)
- IT Immunoglobulins
 - RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (light chains, IgG κ; display vehicles encoding human PrP epitope
 or **anti-β amyloid antibody**
 scFv for diagnosing and/or treating or preventing plaque forming
 diseases)

IT Antibodies
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (monoclonal; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Animal virus
 (neg. strand RNA virus; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Brain, disease
 (plaque forming; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Carriers
 (polypeptide; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Animal virus
 (pos.-strand RNA-containing; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Alzheimer's disease
 (presymptomatic; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Brain, disease
 Prion diseases
 (scrapie; display vehicles encoding human PrP epitope or **anti**-
β amyloid antibody scFv for
 diagnosing and/or treating or preventing plaque forming diseases)

IT Aging, animal
 (senility; display vehicles encoding human PrP epitope or **anti**-
β amyloid antibody scFv for
 diagnosing and/or treating or preventing plaque forming diseases)

IT Animal virus
 (single stranded DNA; display vehicles encoding human PrP epitope or
anti-β amyloid antibody scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT Brain, disease
 (spongiform encephalopathy; display vehicles encoding human PrP epitope or
anti-β amyloid antibody
 scFv for diagnosing and/or treating or preventing plaque forming
 diseases)

IT Alzheimer's disease
 (type I; display vehicles encoding human PrP epitope or **anti-**
β amyloid antibody scFv for diagnosing
 and/or treating or preventing plaque forming diseases)

IT Alzheimer's disease
 (type II; display vehicles encoding human PrP epitope or **anti**-
β amyloid antibody scFv for
 diagnosing and/or treating or preventing plaque forming diseases)

IT Amyloid
 RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU
 (Biological study, unclassified); PRP (Properties); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (β-; display vehicles encoding human PrP epitope or anti
 -β **amyloid antibody** scFv for
 diagnosing and/or treating or preventing plaque forming diseases)

IT 330489-80-0
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; display vehicles encoding human PrP epitope or
 anti-β **amyloid antibody** scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT 91448-99-6P, Cystatin C
 RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU
 (Biological study, unclassified); PRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (display vehicles encoding human PrP epitope or anti-
 β **amyloid antibody** scFv for diagnosing
 and/or treating or preventing plaque forming diseases)

IT 134500-80-4P 148439-49-0P 211373-10-3P 312298-34-3P 312298-35-4P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (display vehicles encoding human PrP epitope or anti-
 β **amyloid antibody** scFv for diagnosing
 and/or treating or preventing plaque forming diseases)

IT 330489-79-7
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; display vehicles encoding human PrP epitope or
 anti-β **amyloid antibody** scFv
 for diagnosing and/or treating or preventing plaque forming diseases)

IT 330490-88-5 330490-89-6 330490-90-9 330490-91-0, 7: PN: WO0118169
 SEQID: 13 unclaimed DNA 330490-92-1, 8: PN: WO0118169 SEQID: 14
 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; agents and compns. and methods
 utilizing same useful in diagnosing and/or treating or preventing
 plaque forming diseases)

IT 122024-47-9 330218-78-5 330218-79-6 330218-80-9 330218-81-0
 330218-82-1 330218-83-2 330218-84-3 330218-85-4 330218-86-5
 330218-87-6 330218-88-7
 RL: PRP (Properties)
 (unclaimed sequence; agents and compns. and methods utilizing same
 useful in diagnosing and/or treating or preventing plaque forming
 diseases)

L52 ANSWER 24 OF 34 ZCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:606944 ZCAPLUS

DN 131:227675

ED Entered STN: 24 Sep 1999

TI Antibodies to β-amyloids or their derivatives and use thereof

IN Suzuki, Nobuhiro; Odaka, Asano; Kitada, Chieko

PA Takeda Chemical Industries, Ltd., Japan

SO U.S., 46 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM C12D021-04

ICS C07K016-00

NCL 435070210

CC 15-3 (Immunochemistry)

Section cross-reference(s) : 4

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5955317	A	19990921	US 1997-986948	19971208 <--
	EP 1308461	A2	20030507	EP 2002-27099	19940124 <--
	EP 1308461	A3	20040211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
PRAI	JP 1993-10132	A	19930125 <--		
	JP 1993-19035	A	19930205 <--		
	JP 1993-286935	A	19931116 <--		
	JP 1993-334733	A	19931228 <--		
	JP 1993-286985	A	19931116 <--		
	JP 1993-334773	A	19931228 <--		
	EP 1994-904758	A3	19940124 <--		
AB	According to this invention, antibodies which are useful and novel in that they have binding specificity to β -amyloids or derivs. thereof, namely recognize the N-terminal, the C-terminal or central portions of the β -amyloids, resp., were obtained. By combining these antibodies, determination methods by which the β -amyloids could be determined sensitively				
and	and specifically are provided. These determination methods are useful for diagnosis				
	of diseases to which the β -amyloids or their derivs. are related (for example, Alzheimer's disease), and the antibodies of this invention are useful for the development of preventive-therapeutic compns. for Alzheimer's disease.				
ST	monoclonal antibody beta amyloid Alzheimer disease				
IT	Alzheimer's disease				
	Hybridoma				
	Protein sequences				
	(monoclonal antibodies to β -amyloids or their derivs. for diagnosis and development of therapeutic of Alzheimer's disease)				
IT	Antibodies				
	RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(monoclonal; monoclonal antibodies to β -amyloids or their derivs. for diagnosis and development of therapeutic of Alzheimer's disease)				
IT	Mental disorder				
	(senile psychosis; monoclonal antibodies to β -amyloids or their derivs. for diagnosis and development of therapeutic of Alzheimer's disease)				
IT	Amyloid				
	RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)				
	(β -; monoclonal antibodies to β -amyloids or their derivs. for diagnosis and development of therapeutic of Alzheimer's disease)				
IT	107761-42-2P , Glycopeptide (human clone 9-110 amyloid A4 peptide moiety) 109770-29-8P, 1-28-Glycopeptide (human clone 9-110 amyloid A4 peptide moiety) 112163-49-2P 115427-62-8P 131438-74-9P 131438-79-4P 131580-10-4P 131580-11-5P 131602-53-4P 134500-80-4P 145110-15-2P, Glycopeptide (Macaca fascicularis amyloid A4 peptide moiety) 158702-36-4P				
	RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(monoclonal antibodies to β -amyloids or their derivs. for diagnosis and development of therapeutic of Alzheimer's disease)				
RE.CNT	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD			
RE					

- (1) Anon; WO 8906242 1989 ZCPLUS
- (2) Anon; WO 9209699 1992 ZCPLUS
- (3) Anon; Supplemental European Search Report mailed Jan 26 1998 application No 94904758 3
- (4) Ghiso; Biochem J 1992, V288, P1053 ZCPLUS
- (5) Morris; Neurology 1989, V39, P1159 MEDLINE
- (6) Seubert; Nature 1992, V359, P325 ZCPLUS
- (7) Seubert; Nature 1992, V359, P332
- (8) Suzuki; US 5750349 1998 ZCPLUS

L52 ANSWER 27 OF 34 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

AN 97229491 EMBASE

DN 1997229491

TI The recognition of haemoglobin by antibodies raised for the immunoassay of β -amyloid.

AU Cutler P.; Brown F.; Camilleri P.; Carpenter D.; George A.; Gray C.; Haran M.; Stewart B.

CS P. Cutler, Smithkline Beecham Pharmaceuticals, New Frontiers Science Park, Cold Harbour Road, The Pinnacles, Harlow, Essex CM19 5AD, United Kingdom

SO FEBS Letters, (1997) 412/2 (341-345).

Refs: 19

ISSN: 0014-5793 CODEN: FEBLAL

PUI S 0014-5793(97)00696-0

CY Netherlands

DT Journal; Article

FS 008 Neurology and Neurosurgery

025 Hematology

029 Clinical Biochemistry

LA English

SL English

AB Canine and porcine cerebrospinal fluid (CSF) were fractionated by size exclusion chromatography and analysed by a luminescence enzyme linked immunosorbent assay (ELISA) configured to detect β -amyloid. A peak of activity was observed in the CSP consistent with the molecular weight of β -amyloid. When CSF contaminated with blood was analysed an additional peak of immunoreactivity at a higher molecular weight was observed. The peak of activity was found to be derived from cross-reactivity of the immunoglobulins employed in the ELISA with haemoglobin. These findings are discussed with reference to primary and structural sequence homology between β -amyloid and haemoglobin from a number of species, the known properties of β -amyloid and recent clinical reports.

CT Medical Descriptors:

*enzyme linked immunosorbent assay

*protein analysis

alzheimer disease: DI, diagnosis

animal tissue

article

cattle

controlled study

cross reaction

dog

gel permeation chromatography

human

human tissue

nonhuman

priority journal

swine

Drug Descriptors:

*amyloid beta protein: EC, endogenous compound
 *antibody
 *hemoglobin
 RN (amyloid beta protein) 109770-29-8; (hemoglobin) 9008-02-0

L52 ANSWER 30 OF 34 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 94176340 EMBASE
 DN 1994176340
 TI Early diagnosis of Alzheimer's [10].
 AU Kishikawa M.; Iseki M.; Sakae M.; Kawaguchi S.; Fujii H.; Talamo B.R.
 CS Department of Pathology, SDCABD, Nagasaki Univ. School of Medicine, 1-12-4
 Sakamoto, Nagasaki 852, Japan
 SO Nature, (1994) 369/6479 (365-366).
 ISSN: 0028-0836 CODEN: NATUAS
 CY United Kingdom
 DT Journal; Letter
 FS 005 General Pathology and Pathological Anatomy
 008 Neurology and Neurosurgery
 LA English
 CT Medical Descriptors:
 *alzheimer disease: DI, diagnosis
 *neurofibrillary tangle
 *olfactory epithelium
 *olfactory nerve
 early diagnosis
 hippocampus
 human
 immunohistology
 letter
 priority journal
 Drug Descriptors:
 *amyloid beta protein: EC, endogenous compound
 *antibody
 RN *tau protein: EC, endogenous compound
 (amyloid beta protein) 109770-29-8

L52 ANSWER 33 OF 34 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 90336517 EMBASE
 DN 1990336517
 TI Detection and quantitation of amyloid B-peptide with 2 monoclonal
 antibodies.
 AU Kim K.S.; Wen G.Y.; Bancher C.; Chen C.M.J.; Sapienza V.J.; Hong H.;
 Wisniewski H.M.
 CS New York State Institute for Basic Research in Developmental Disabilities,
 1050 Forest Hill Road, Staten Island, NY 10314, United States
 SO Neuroscience Research Communications, (1990) 7/2 (113-122).
 ISSN: 0893-6609 CODEN: NRCOEE
 CY United Kingdom
 DT Journal; Article
 FS 002 Physiology
 005 General Pathology and Pathological Anatomy
 008 Neurology and Neurosurgery
 020 Gerontology and Geriatrics
 032 Psychiatry
 LA English
 CT Medical Descriptors:
 *alzheimer disease: DI, diagnosis
 *senile plaque

cytochemistry

human cell

human

article

Drug Descriptors:

*amyloid

*antibody

RN (amyloid) 11061-24-8

L52 ANSWER 34 OF 34 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

AN 89128239 EMBASE

DN 1989128239

TI An antiserum against amyloid β -protein precursor detects a unique peptide in Alzheimer brain.

AU Cole G.; Masliah E.; Huynh T.V.; DeTeresa R.; Terry R.D.; Okuda C.; Saitoh T.

CS Department of Neurosciences, University of California, School of Medicine, La Jolla, San Diego, CA 92093, United States

SO Neuroscience Letters, (1989) 100/1-3 (340-346).

ISSN: 0304-3940 CODEN: NELED5

CY Netherlands

DT Journal

FS 008 Neurology and Neurosurgery

029 Clinical Biochemistry

LA English

SL English

AB An antiserum was raised against an amino acid sequence predicted from the DNA sequence of amyloid β -protein precursor (ABPP), and it was then affinity-purified. This affinity-purified antibody (anti-GID) intensely stained neurons and dystrophic neurites in plaques of Alzheimer's disease (AD) patients, but marginally stained neurons of age-matched normal individuals. Anti-GID antibody detected a series of protein bands with a molecular weight centered at 100,000 and a second band at 55,000 on a blot of the human brain particulate fraction. It also stained a set of bands with a molecular weight around 95,000 and a doublet of M(r) 16,000 in the soluble fraction. A band at M(r) 35,000 was detected in the soluble fraction prepared from brain tissue of AD patients but not from control brain tissue. A strong immunostaining of AD sections with anti-GID and the presence of a M(r) 35,000 band unique to AD might reflect an altered processing of ABPP in AD brains.

CT Medical Descriptors:

*alzheimer disease: DI, diagnosis

*alzheimer disease: ET, etiology

*senile plaque

autopsy

histochemistry

immunoblotting

controlled study

clinical article

human cell

human

priority journal

Drug Descriptors:

*amyloid

*antibody

RN (amyloid) 11061-24-8

=> b home

Chernyshev 10/099,880

Page 30

FILE 'HOME' ENTERED AT 13:37:15 ON 04 JUN 2004

Searched by P. Ruppel